Skip to main content
SpringerLink
Log in

Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Anti-PD-1/PD-L1 therapies have demonstrated activity in patients with advanced stage non-small cell lung cancer (NSCLC). However, little is known about the safety and feasibility of patients receiving anti-PD-1/PD-L1 therapy and stereotactic radiation for the treatment of brain metastases. Data were analyzed retrospectively from NSCLC patients treated with stereotactic radiation either before, during or after anti-PD-1/PD-L1 therapy with nivolumab (anti-PD-1) or durvalumab (anti-PD-L1). Seventeen patients treated with stereotactic radiosurgery (SRS) or fractionated stereotactic radiation therapy (FSRT) to 49 brain metastases over 21 sessions were identified. Radiation was administered prior to, during and after anti-PD-1/PD-L1 therapy in 22 lesions (45%), 13 lesions (27%), and 14 lesions (29%), respectively. The 6 months Kaplan–Meier (KM) distant brain control rate was 48% following stereotactic radiation. Six and 12 month KM rates of OS from the date of stereotactic radiation and the date of cranial metastases diagnosis were 48/41% and 81/51%, respectively. The 6 month rate of distant brain control following stereotactic radiation for patients treated with stereotactic radiation during or prior to anti-PD-1/PD-L1 therapy was 57% compared to 0% among patients who received anti-PD-1/PD-L1 therapy before stereotactic radiation (p = 0.05). A Karnofsky Performance Status (KPS) of <90 was found to be predictive of worse OS following radiation treatment on both univariate and multivariate analyses (MVA, p = 0.01). In our series, stereotactic radiation to NSCLC brain metastases was well tolerated in patients who received anti-PD-1/PD-L1 therapy. Prospective evaluation to determine how these two modalities can be used synergistically to improve distant brain control and OS is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Sorensen JB, Hansen HH, Hansen M, Dombernowsky P (1988) Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 6:1474–1480

    Article  CAS  PubMed  Google Scholar 

  2. Schouten LJ, Rutten J, Huveneers HA, Twijnstra A (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94:2698–2705

    Article  PubMed  Google Scholar 

  3. Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI (1999) Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 43:795–803

    Article  CAS  PubMed  Google Scholar 

  4. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419–425. doi:10.1200/JCO.2011.38.0527

    Article  PubMed  Google Scholar 

  5. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639. doi:10.1056/NEJMoa1507643

    Article  CAS  PubMed  Google Scholar 

  6. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Aren Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135. doi:10.1056/NEJMoa1504627

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, Investigators K- (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028. doi:10.1056/NEJMoa1501824

    Article  PubMed  Google Scholar 

  8. Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, Narwal R, Steele K, Gu Y, Karakunnel JJ, Rizvi NA (2016) Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 17:299–308. doi:10.1016/S1470-2045(15)00544-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Ahmed KA, Stallworth DG, Kim Y, Johnstone PA, Harrison LB, Caudell JJ, Yu HH, Etame AB, Weber JS, Gibney GT (2015) Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol. doi:10.1093/annonc/mdv622

    PubMed  Google Scholar 

  10. Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL (2012) Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 117:227–233. doi:10.3171/2012.5.JNS111929

    Article  PubMed  Google Scholar 

  11. Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT, Chan TA, Yamada Y, Beal K (2015) Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92:368–375. doi:10.1016/j.ijrobp.2015.01.004

    Article  PubMed  PubMed Central  Google Scholar 

  12. Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD (2013) Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2:899–906. doi:10.1002/cam4.140

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Qian JM, Yu JB, Kluger HM, Chiang VL (2016) Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer 122:3051–3058. doi:10.1002/cncr.30138

    Article  CAS  PubMed  Google Scholar 

  14. Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA (2015) Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 16:e534–e542. doi:10.1016/S1470-2045(15)00088-1

    Article  PubMed  PubMed Central  Google Scholar 

  15. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S (2009) Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clinical Cancer Res 15:5379–5388. doi:10.1158/1078-0432.CCR-09-0265

    Article  CAS  Google Scholar 

  16. Schaue D, Ratikan JA, Iwamoto KS, McBride WH (2012) Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 83:1306–1310. doi:10.1016/j.ijrobp.2011.09.049

    Article  CAS  PubMed  Google Scholar 

  17. Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, Durham N, Meyer C, Harris TJ, Albesiano E, Pradilla G, Ford E, Wong J, Hammers HJ, Mathios D, Tyler B, Brem H, Tran PT, Pardoll D, Drake CG, Lim M (2013) Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 86:343–349. doi:10.1016/j.ijrobp.2012.12.025

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM (2005) Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 174:7516–7523

    Article  CAS  PubMed  Google Scholar 

  19. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA, Young B (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280:1485–1489

    Article  CAS  PubMed  Google Scholar 

  20. Aoyama H, Tago M, Kato N, Toyoda T, Kenjyo M, Hirota S, Shioura H, Inomata T, Kunieda E, Hayakawa K, Nakagawa K, Kobashi G, Shirato H (2007) Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 68:1388–1395. doi:10.1016/j.ijrobp.2007.03.048

    Article  PubMed  Google Scholar 

  21. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10:1037–1044. doi:10.1016/S1470-2045(09)70263-3

    Article  PubMed  Google Scholar 

  22. Tallet AV, Azria D, Barlesi F, Spano JP, Carpentier AF, Goncalves A, Metellus P (2012) Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiat Oncol 7:77. doi:10.1186/1748-717X-7-77

    Article  PubMed  PubMed Central  Google Scholar 

  23. Gerosa M, Nicolato A, Foroni R, Tomazzoli L, Bricolo A (2005) Analysis of long-term outcomes and prognostic factors in patients with non-small cell lung cancer brain metastases treated by gamma knife radiosurgery. J Neurosurg 102:75–80

    Article  Google Scholar 

  24. Serizawa T, Ono J, Iichi T, Matsuda S, Sato M, Odaki M, Hirai S, Osato K, Saeki N, Yamaura A (2002) Gamma knife radiosurgery for metastatic brain tumors from lung cancer: a comparison between small cell and non-small cell carcinoma. J Neurosurg 97:484–488. doi:10.3171/jns.2002.97.supplement

    PubMed  Google Scholar 

  25. Ma LH, Li G, Zhang HW, Wang ZY, Dang J, Zhang S, Yao L, Zhang XM (2012) Hypofractionated stereotactic radiotherapy with or without whole-brain radiotherapy for patients with newly diagnosed brain metastases from non-small cell lung cancer. J Neurosurg 117:49–56. doi:10.3171/2012.7.GKS121071

    PubMed  Google Scholar 

  26. Motta M, del Vecchio A, Attuati L, Picozzi P, Perna L, Franzin A, Bolognesi A, Cozzarini C, Calandrino R, Mortini P, di Muzio N (2011) Gamma knife radiosurgery for treatment of cerebral metastases from non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 81:e463–e468. doi:10.1016/j.ijrobp.2011.02.051

    Article  PubMed  Google Scholar 

  27. Mariya Y, Sekizawa G, Matsuoka Y, Seki H, Sugawara T (2010) Outcome of stereotactic radiosurgery for patients with non-small cell lung cancer metastatic to the brain. J Radiat Res 51:333–342

    Article  PubMed  Google Scholar 

  28. Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD (2002) Radiosurgery for non-small cell lung carcinoma metastatic to the brain: long-term outcomes and prognostic factors influencing patient survival time and local tumor control. J Neurosurg 97:1276–1281. doi:10.3171/jns.2002.97.6.1276

    Article  PubMed  Google Scholar 

  29. Tamari K, Suzuki O, Hashimoto N, Kagawa N, Fujiwara M, Sumida I, Seo Y, Isohashi F, Yoshioka Y, Yoshimine T, Ogawa K (2015) Treatment outcomes using CyberKnife for brain metastases from lung cancer. J Radiat Res 56:151–158. doi:10.1093/jrr/rru092

    Article  PubMed  Google Scholar 

  30. Goldman JW, Crino L, Vokes EE, Holgado E, Reckamp K, Pluzanski A, Spigel DR, Kohlhaeufl M, Garassino MC, Chow L, Gettinger SN, Gerber DE, Havel L, Ramalingam SS, Dy GK, Geese WJ, Li A, Blackwood-Chirchir A, Healey DI, Brahmer JR (2016) Nivolumab in patients with advanced NSCLC and central nervous system metastases. J Clin Oncol Off J Am Soc Clin Oncol 34:suppl abstract 9038

  31. Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17:976–983. doi:10.1016/S1470-2045(16)30053-5

    Article  CAS  PubMed  Google Scholar 

  32. Berghoff AS, Ricken G, Widhalm G, Rajky O, Dieckmann K, Birner P, Bartsch R, Holler C, Preusser M (2015) Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology 66:289–299. doi:10.1111/his.12537

    Article  PubMed  Google Scholar 

  33. Berghoff AS, Inan C, Ricken G, Widhalm G, Dieckmann K, Birner P, Oberndorfer F, Dome B, Bartsch R, Zielinski C, Preusser M (2014) Tumor-infiltrating lymphocytes (TILS) and PD-L1 expression in non-small cell lung cancer brain metastases (BM) and matched primary tumors (PT). Ann Oncol 25:iv465-iv466

    Google Scholar 

  34. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ (2015) Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520:373–377. doi:10.1038/nature14292

    Article  CAS  PubMed  Google Scholar 

  35. Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A, Gomez D, Ye H, Heymach J, Komaki R, Allison JP, Sharma P, Welsh JW (2014) Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res 2:831–838. doi:10.1158/2326-6066.CIR-14-0069

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Filippi AR, Fava P, Badellino S, Astrua C, Ricardi U, Quaglino P (2016) Radiotherapy and immune checkpoints inhibitors for advanced melanoma. Radiother Oncol 120:1–12. doi:10.1016/j.radonc.2016.06.003

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902, Magnolia Drive, Tampa, FL, 33612, USA

    Kamran A. Ahmed, Sungjune Kim, Arash O. Naghavi, Thomas J. Dilling, Jimmy J. Caudell, Louis B. Harrison, Peter A. Johnstone, Michael Yu & Bradford A. Perez

  2. Department of Radiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA

    John Arrington

  3. Department of Thoracic-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA

    Ben C. Creelan, Scott J. Antonia & Jhanelle E. Gray

  4. Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA

    Solmaz Sahebjam & Arnold B. Etame

Authors
  1. Kamran A. Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sungjune Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John Arrington
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arash O. Naghavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thomas J. Dilling
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ben C. Creelan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Scott J. Antonia
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jimmy J. Caudell
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Louis B. Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Solmaz Sahebjam
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jhanelle E. Gray
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Arnold B. Etame
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Peter A. Johnstone
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Michael Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Bradford A. Perez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bradford A. Perez.

Ethics declarations

Conflict of interest

The authors have no conflicts to disclose.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ahmed, K.A., Kim, S., Arrington, J. et al. Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. J Neurooncol 133, 331–338 (2017). https://doi.org/10.1007/s11060-017-2437-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-017-2437-5

Keywords

Search

Navigation